|
Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia
|
|
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|
|
Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma
|
|
A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader
|
|
Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia
|
|
Spotting the elusive Siberian tiger: Complete response to ibrutinib in a patient with Waldenström Macroglobulinemia
|
|
Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia
|
|
iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia
|
|
The real world of Waldenström's macroglobulinaemia
|
|
Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia
|
|
Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191
|
|
Genomic Landscape of Waldenström Macroglobulinemia
|
|
Initial Evaluation of the Patient with Waldenström Macroglobulinemia
|
|
Waldenström Macroglobulinemia: Lessons Learned from Basic and Clinical Research
|
|
Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia
|
|
Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients
|
|
MYD88 mutated and wild-type Waldenströms Macroglobulinemia: Characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4
|
|
Extracellular vesicle-mediated transfer of constitutively active MyD88L265P engages MyD88supwt and activates signaling
|
|
Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia
|
|
BTK Cys481Ser drives ibrutinib resistance via ERK1/2, and protects BTK Wild-Type MYD88 mutated cells by a paracrine mechanism
|
|
Ibrutinib Withdrawal Symptoms in Patients with Waldenström Macroglobulinemia
|
|
Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia
|
|
Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia
|
|
Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound
|
|
MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival
|
